These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

66 related articles for article (PubMed ID: 22521768)

  • 1. Drug-interaction studies evaluating T-cell proliferation reveal distinct activity of dasatinib and imatinib in combination with cyclosporine A.
    Blake SJ; Hughes TP; Lyons AB
    Exp Hematol; 2012 Aug; 40(8):612-21.e6. PubMed ID: 22521768
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dasatinib exerts an immunosuppressive effect on CD8+ T cells specific for viral and leukemia antigens.
    Fei F; Yu Y; Schmitt A; Rojewski MT; Chen B; Greiner J; Götz M; Guillaume P; Döhner H; Bunjes D; Schmitt M
    Exp Hematol; 2008 Oct; 36(10):1297-308. PubMed ID: 18619726
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Imatinib inhibits the activation and proliferation of normal T lymphocytes in vitro.
    Cwynarski K; Laylor R; Macchiarulo E; Goldman J; Lombardi G; Melo JV; Dazzi F
    Leukemia; 2004 Aug; 18(8):1332-9. PubMed ID: 15190258
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Imatinib mesylate, a new kid on the block for the treatment of anti-neutrophil cytoplasmic autoantibodies-associated vasculitis?
    Kälsch AI; Soboletzki M; Schmitt WH; van der Woude FJ; Hochhaus A; Yard BA; Birck R
    Clin Exp Immunol; 2008 Mar; 151(3):391-8. PubMed ID: 18190601
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dasatinib as salvage therapy for steroid refractory and imatinib resistant or intolerant sclerotic chronic graft-versus-host disease.
    Sánchez-Ortega I; Servitje O; Arnan M; Ortí G; Peralta T; Manresa F; Duarte RF
    Biol Blood Marrow Transplant; 2012 Feb; 18(2):318-23. PubMed ID: 22068151
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Src/ABL kinase inhibitor dasatinib (BMS-354825) inhibits function of normal human T-lymphocytes in vitro.
    Blake S; Hughes TP; Mayrhofer G; Lyons AB
    Clin Immunol; 2008 Jun; 127(3):330-9. PubMed ID: 18395492
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Once-daily dasatinib for treatment of patients with chronic myeloid leukemia.
    Tyler T
    Ann Pharmacother; 2009 May; 43(5):920-7. PubMed ID: 19336654
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Costimulatory signals modulate the antiproliferative effects of agents that elevate cAMP in T cells.
    Bartik MM; Bauman GP; Brooks WH; Roszman TL
    Cell Immunol; 1994 Oct; 158(1):116-30. PubMed ID: 8087859
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Recurrent neutrophilic panniculitis in a patient with chronic myelogenous leukaemia treated with imatinib mesilate and dasatinib].
    de Masson A; Bouvresse S; Clérici T; Mahé E; Saïag P
    Ann Dermatol Venereol; 2011 Feb; 138(2):135-9. PubMed ID: 21333826
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evidence for the involvement of three distinct signals in the induction of IL-2 gene expression in human T lymphocytes.
    June CH; Ledbetter JA; Lindsten T; Thompson CB
    J Immunol; 1989 Jul; 143(1):153-61. PubMed ID: 2543699
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dasatinib, a small-molecule protein tyrosine kinase inhibitor, inhibits T-cell activation and proliferation.
    Schade AE; Schieven GL; Townsend R; Jankowska AM; Susulic V; Zhang R; Szpurka H; Maciejewski JP
    Blood; 2008 Feb; 111(3):1366-77. PubMed ID: 17962511
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias.
    Talpaz M; Shah NP; Kantarjian H; Donato N; Nicoll J; Paquette R; Cortes J; O'Brien S; Nicaise C; Bleickardt E; Blackwood-Chirchir MA; Iyer V; Chen TT; Huang F; Decillis AP; Sawyers CL
    N Engl J Med; 2006 Jun; 354(24):2531-41. PubMed ID: 16775234
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A review of deferasirox, bortezomib, dasatinib, and cyclosporine eye drops: possible uses and known side effects in cutaneous medicine.
    Scheinfeld N
    J Drugs Dermatol; 2007 Mar; 6(3):352-5. PubMed ID: 17373201
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification and functional signature of genes regulated by structurally different ABL kinase inhibitors.
    Nunoda K; Tauchi T; Takaku T; Okabe S; Akahane D; Sashida G; Ohyashiki JH; Ohyashiki K
    Oncogene; 2007 Jun; 26(28):4179-88. PubMed ID: 17213809
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Crosslinking of CD27 in the presence of CD28 costimulation results in T cell proliferation and cytokine production.
    Sunder-Plassmann R; Pickl WF; Majdic O; Knapp W; Holter W
    Cell Immunol; 1995 Aug; 164(1):20-7. PubMed ID: 7634349
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dasatinib overrides imatinib resistance mediated by the F359I residue mutation in two patients with chronic myeloid leukemia.
    Serpa M; Sanabani SS; Dorlhiac-Llacer PE; Nardinelli L; de Barros Ferreira P; Martins TF; Seguro F; Bendit I
    Acta Haematol; 2012; 127(1):56-9. PubMed ID: 22094354
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bortezomib can suppress activation of rapamycin-resistant memory T cells without affecting regulatory T-cell viability in non-human primates.
    Kim JS; Lee JI; Shin JY; Kim SY; Shin JS; Lim JH; Cho HS; Yoon IH; Kim KH; Kim SJ; Park CG
    Transplantation; 2009 Dec; 88(12):1349-59. PubMed ID: 20029331
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of T-cell activation in vitro in human peripheral blood mononuclear cells by pimecrolimus and glucocorticosteroids and combinations thereof.
    Winiski A; Wang S; Schwendinger B; Stuetz A
    Exp Dermatol; 2007 Aug; 16(8):699-704. PubMed ID: 17620098
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of FK506 on the interleukin 15-driven proliferation and apoptosis of anti-CD3-activated umbilical cord blood T cells.
    Lin SJ; Yan DC; Kuo ML; Cheng PJ; Hsiao SS; Tsai TL
    Ann Allergy Asthma Immunol; 2005 Dec; 95(6):586-92. PubMed ID: 16400900
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dasatinib: from treatment of imatinib-resistant or -intolerant patients with chronic myeloid leukemia to treatment of patients with newly diagnosed chronic phase chronic myeloid leukemia.
    Abbott BL
    Clin Ther; 2012 Feb; 34(2):272-81. PubMed ID: 22285209
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.